VERICEL CORPORATION Comprehensive Income
VERICEL CORPORATION (VCEL) reported Comprehensive Income of $2.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-30
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $2.01M.
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$6.75M.
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $23.26M, a 19.58% increase year-over-year.
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $5.15M.
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $16.79M, a 60.41% increase from fiscal 2024.
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $10.47M.
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$2.30M.
- VERICEL CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$17.53M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-07-30 | -$4.74M 10-Q · filed 2026-07-30 | $18.52M derived: sum of 3 quarters · filed 2026-07-30 | $23.67M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$6.75M 10-Q · filed 2026-05-07 | $16.52M derived: sum of 2 quarters · filed 2026-05-07 | $21.66M derived: sum of 3 quarters · filed 2026-05-07 | $21.16M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $23.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $28.41M derived: sum of 2 quarters · filed 2026-02-26 | $27.90M derived: sum of 3 quarters · filed 2026-07-30 | $16.79M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $5.15M 10-Q · filed 2025-11-06 | $4.64M derived: sum of 2 quarters · filed 2026-07-30 | -$6.47M 10-Q · filed 2025-11-06 | $12.98M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$506.00K 10-Q · filed 2026-07-30 | -$11.62M 10-Q · filed 2026-07-30 | $7.83M derived: sum of 3 quarters · filed 2026-07-30 | $7.56M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$11.11M 10-Q · filed 2026-05-07 | $8.34M derived: sum of 2 quarters · filed 2026-05-07 | $8.07M derived: sum of 3 quarters · filed 2026-05-07 | $3.36M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.18M derived: sum of 2 quarters · filed 2026-02-26 | $14.47M derived: sum of 3 quarters · filed 2026-02-26 | $10.47M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$269.00K 10-Q · filed 2025-11-06 | -$4.98M derived: sum of 2 quarters · filed 2025-11-06 | -$8.99M 10-Q · filed 2025-11-06 | $4.37M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$4.71M 10-Q · filed 2025-07-31 | -$8.72M 10-Q · filed 2025-07-31 | $4.64M derived: sum of 3 quarters · filed 2026-02-26 | $1.14M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$4.01M 10-Q · filed 2025-05-08 | $9.35M derived: sum of 2 quarters · filed 2026-02-26 | $5.85M derived: sum of 3 quarters · filed 2026-02-26 | $842.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $13.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.85M derived: sum of 2 quarters · filed 2026-02-26 | $4.85M derived: sum of 3 quarters · filed 2026-02-26 | -$2.30M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$3.50M 10-Q · filed 2024-11-07 | -$8.51M derived: sum of 2 quarters · filed 2024-11-07 | -$15.66M 10-Q · filed 2024-11-07 | -$9.57M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$5.00M 10-Q · filed 2024-08-01 | -$12.16M 10-Q · filed 2024-08-01 | -$6.07M derived: sum of 3 quarters · filed 2025-02-27 | -$12.94M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$7.15M 10-Q · filed 2024-05-08 | -$1.06M derived: sum of 2 quarters · filed 2025-02-27 | -$7.93M derived: sum of 3 quarters · filed 2025-02-27 | -$17.14M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$778.00K derived: sum of 2 quarters · filed 2025-02-27 | -$9.98M derived: sum of 3 quarters · filed 2025-02-27 | -$17.53M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$6.87M 10-Q · filed 2023-11-08 | -$16.07M derived: sum of 2 quarters · filed 2023-11-08 | -$23.62M 10-Q · filed 2023-11-08 | -$19.22M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | -$9.21M 10-Q · filed 2023-08-02 | -$16.75M 10-Q · filed 2023-08-02 | -$12.35M derived: sum of 3 quarters · filed 2024-02-29 | -$17.28M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | -$7.55M 10-Q · filed 2023-05-10 | -$3.15M derived: sum of 2 quarters · filed 2024-02-29 | -$8.08M derived: sum of 3 quarters · filed 2024-02-29 | -$11.84M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$527.00K derived: sum of 2 quarters · filed 2024-02-29 | -$4.29M derived: sum of 3 quarters · filed 2024-02-29 | -$7.64M 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$4.93M 10-Q · filed 2022-11-09 | -$8.69M derived: sum of 2 quarters · filed 2022-11-09 | -$12.04M 10-Q · filed 2022-11-09 | $113.00K derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | -$3.76M 10-Q · filed 2022-08-03 | -$7.11M 10-Q · filed 2022-08-03 | $5.04M derived: sum of 3 quarters · filed 2023-02-23 | $8.59M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | -$3.35M 10-Q · filed 2022-05-04 | $8.81M derived: sum of 2 quarters · filed 2023-02-23 | $12.36M derived: sum of 3 quarters · filed 2023-02-23 | $4.17M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $12.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $15.71M derived: sum of 2 quarters · filed 2023-02-23 | $7.52M derived: sum of 3 quarters · filed 2023-02-23 | $2.86M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $3.55M 10-Q · filed 2021-11-09 | -$4.63M derived: sum of 2 quarters · filed 2021-11-09 | -$9.30M 10-Q · filed 2021-11-09 | $233.00K derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | -$8.19M 10-Q · filed 2021-08-04 | -$12.85M 10-Q · filed 2021-08-04 | -$3.32M derived: sum of 3 quarters · filed 2022-02-24 | $144.00K derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$4.66M 10-Q · filed 2021-05-05 | $4.87M derived: sum of 2 quarters · filed 2022-02-24 | $8.33M derived: sum of 3 quarters · filed 2022-02-24 | -$11.43M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $9.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $12.99M derived: sum of 2 quarters · filed 2022-02-24 | -$6.76M derived: sum of 3 quarters · filed 2022-02-24 | -$9.61M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $3.46M 10-Q · filed 2020-11-05 | -$16.30M derived: sum of 2 quarters · filed 2020-11-05 | -$19.14M 10-Q · filed 2020-11-05 | -$13.88M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | -$19.76M 10-Q · filed 2020-08-05 | -$22.60M 10-Q · filed 2020-08-05 | -$17.34M derived: sum of 3 quarters · filed 2021-02-24 | -$18.43M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | -$2.80M 10-Q · filed 2020-05-11 | $2.42M derived: sum of 2 quarters · filed 2021-02-24 | $1.33M derived: sum of 3 quarters · filed 2021-02-24 | -$3.32M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $4.13M derived: sum of 2 quarters · filed 2021-02-24 | -$517.00K derived: sum of 3 quarters · filed 2021-02-24 | -$8.18M 10-K · filed 2021-02-24 | |
| 2018-09-30 | -$1.09M 10-Q · filed 2019-11-05 | -$5.74M derived: sum of 2 quarters · filed 2019-11-05 | -$13.40M 10-Q · filed 2019-11-05 | -$13.11M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | -$4.65M 10-Q · filed 2019-08-06 | -$12.31M 10-Q · filed 2019-08-06 | -$12.02M derived: sum of 3 quarters · filed 2020-02-25 | -$17.43M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-03-31 | -$7.66M 10-Q · filed 2019-05-07 | -$7.37M derived: sum of 2 quarters · filed 2020-02-25 | -$12.78M derived: sum of 3 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$5.12M derived: sum of 2 quarters · filed 2020-02-25 | -$17.29M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | -$5.41M 10-Q · filed 2018-11-06 | -$17.57M 10-Q · filed 2018-11-06 | |||
| 2016-12-31 | -$19.57M 10-K · filed 2019-02-26 | ||||
| 2016-06-30 | -$3.04M 10-Q · filed 2016-08-08 | -$6.69M derived: sum of 2 quarters · filed 2016-08-08 | -$11.53M derived: sum of 3 quarters · filed 2018-03-05 | -$15.95M derived: sum of 4 quarters · filed 2018-03-05 | |
| 2016-03-31 | -$3.65M 10-Q · filed 2016-05-10 | -$8.49M derived: sum of 2 quarters · filed 2018-03-05 | -$12.90M derived: sum of 3 quarters · filed 2018-03-05 | -$15.06M derived: sum of 4 quarters · filed 2018-03-05 | |
| 2015-12-31 | -$4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$9.26M derived: sum of 2 quarters · filed 2018-03-05 | -$11.41M derived: sum of 3 quarters · filed 2018-03-05 | -$16.27M 10-K · filed 2018-03-05 | |
| 2015-09-30 | -$4.42M 10-Q · filed 2015-11-13 | -$6.57M derived: sum of 2 quarters · filed 2015-11-13 | -$11.43M 10-Q · filed 2015-11-13 | -$11.09M derived: sum of 4 quarters · filed 2017-03-13 | |
| 2015-06-30 | -$2.15M 10-Q · filed 2015-08-12 | -$7.01M 10-Q · filed 2015-08-12 | -$6.67M derived: sum of 3 quarters · filed 2017-03-13 | -$13.67M derived: sum of 4 quarters · filed 2017-03-13 | |
| 2015-03-31 | -$2.15M 10-Q · filed 2016-08-08 | -$4.93M 10-Q · filed 2015-05-14 | -$4.52M derived: sum of 2 quarters · filed 2017-03-13 | -$11.52M derived: sum of 3 quarters · filed 2017-03-13 | -$16.15M derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$9.36M derived: sum of 2 quarters · filed 2017-03-13 | -$14.00M derived: sum of 3 quarters · filed 2017-03-13 | -$19.99M 10-K · filed 2017-03-13 | |
| 2014-09-30 | -$6.99M 10-Q · filed 2015-11-13 | -$11.63M derived: sum of 2 quarters · filed 2015-11-13 | -$17.62M 10-Q · filed 2015-11-13 | -$20.54M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2014-06-30 | -$4.63M 10-Q · filed 2015-08-12 | -$10.63M 10-Q · filed 2015-08-12 | -$13.54M derived: sum of 3 quarters · filed 2016-03-14 | -$15.82M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2014-03-31 | -$6.00M 10-Q · filed 2015-05-14 | -$8.91M derived: sum of 2 quarters · filed 2016-03-14 | -$11.18M derived: sum of 3 quarters · filed 2016-03-14 | -$16.07M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2013-12-31 | -$2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$5.19M derived: sum of 2 quarters · filed 2016-03-14 | -$10.08M derived: sum of 3 quarters · filed 2016-03-14 | -$15.62M 10-K · filed 2016-03-14 | |
| 2013-09-30 | -$2.27M 10-Q · filed 2014-11-13 | -$7.16M derived: sum of 2 quarters · filed 2014-11-13 | -$12.71M 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | -$4.89M 10-Q · filed 2014-08-14 | -$10.43M 10-Q · filed 2014-08-14 | |||
| 2012-12-31 | -$29.47M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |